...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?
【24h】

Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

机译：IL-17a可以是糖尿病肾病的新型治疗靶标吗？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy.
机译：近年来慢性肾病已成为全球性普遍存在的普及率高，其与过早死亡率以及其社会和经济影响。许多患者逐渐进展到末期肾病（ESRD），需要透析和肾移植。目前，大约40％的糖尿病患者发育肾病，使其成为ESRD最普遍的原因。因此，需要更有效的糖尿病肾病治疗。在对糖尿病的临床前研究中，抗炎治疗策略已被用于保护肾脏。最近的证据支持免疫细胞在糖尿病肾病的发病机制中发挥着积极作用。最近，Th17免疫细胞及其效应细胞因子IL-17A在几种临床病症中被出现为有前途的靶标，包括肾病。在这里，我们审查了关于Th17 / IL-17A在糖尿病肾损伤的成因中的参与的目前的知识，以及靶向IL-17A的基本原理作为糖尿病肾病患者的额外治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号